Pharmaceutical Products

pill2

RXUKNONP00238a(3) | Date of preparation: September 2016

  • Products
Avastin® (bevacizumab)

Avastin® (bevacizumab)

 

Avastin® is used alongside common therapies for certain types of breast, colorectal, ovarian, cervical, lung and renal cancer.

(This is a brief indication for use; for details see SPC) 

SPC - Avastin® 25mg/ml Concentrate for Solution for Infusion
PIL - Avastin® 25mg/ml Concentrate for Solution for Infusion

 

RXUKNONP00238b | Date of preparation: November 2015

 

Bondronat® (ibandronic acid)

Bondronat® (ibandronic acid)

For the prevention of skeletal events in patients with breast cancer and bone metastases and treatment of tumour-induced hypercalcaemia.

(This is a brief indication for use; for details see SPC) 

SPC - Bondronat® 2mg Concentrate for Solution for Infusion
SPC - Bondronat® 6mg Concentrate for Solution for Infusion
PIL - Bondronat® 2mg/2ml Concentrate for Solution for Infusion
PIL - Bondronat® 50 mg Film-Coated Tablets
SPC - Bondronat® 50mg Film-Coated Tablets
PIL - Bondronat® 6mg/6ml Concentrate for Solution for Infusion

 

RXUKNONP00238c | Date of preparation: November 2015

Bonviva® (ibandronic acid)

Bonviva® (ibandronic acid)

 

For the treatment of osteoporosis in postmenopausal women at increased risk of fracture.

(This is a brief indication for use; for details see SPC) 

PIL - Bonviva® 150mg Film Coated Tablets
SPC - Bonviva® 150mg Film Coated Tablets
SPC - Bonviva® 3mg/3ml Solution for Injection in Pre-Filled Syringe
PIL - Bonviva® 3mg/3ml Solution for Injection in Pre-Filled Syringe

 

RXUKNONP00238d | Date of preparation: November 2015

 

Cellcept® (mycophenolate mofetil)

Cellcept® (mycophenolate mofetil)

 

Used in the prevention of organ rejection in patients receiving kidney, heart, or liver transplants.

(This is a brief indication for use; for details see SPC) 

SPC - CellCept® 1g/5ml Powder for Oral Suspension
PIL - CellCept® 1g/5ml Powder for Oral Suspension
SPC - Cellcept® 250mg Capsules
PIL - Cellcept® 250mg Capsules
SPC - Cellcept® 500mg Powder
PIL - Cellcept® 500mg Powder
SPC - Cellcept® 500mg Tablets
PIL - Cellcept® 500mg Tablets

 

RXUKNONP00238e | Date of preparation: November 2015

 

Copegus® (ribavirin)

Copegus® (ribavirin)

 

Used in combination with other drugs in the treatment of Hepatitis C.

(This is a brief indication for use; for details see SPC) 

SPC - Copegus® 200mg Film-Coated Tablets
SPC - Copegus® 400mg Film-Coated Tablets
PIL - Copegus® 200mg Film-Coated Tablets
PIL - Copegus® 400mg Film-Coated Tablets

 

RXUKNONP00238f | Date of preparation: November 2015

 

Cotellic® ▼ (cobimetinib)

Cotellic® ▼ (cobimetinib)

 

Indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

SPC - Cotellic® 20 mg film-coated tablets
PIL - Cotellic® 20 mg film-coated tablets

 

RXUKNONP00238am | Date of preparation: January 2016

 

Cymevene® (ganciclovir)

Cymevene® (ganciclovir)

 

Used in the treatment of cytomegalovirus (CMV) infections in immunocompromised patients, including AIDS and organ transplant patients, and the prevention of CMV in transplant patients.

(This is a brief indication for use; for details see SPC) 

SPC - Cymevene® IV
PIL - Cymevene® IV

 

RXUKNONP00238g | Date of preparation: November 2015

 

Erivedge® ▼ (vismodegib)

Erivedge® ▼ (vismodegib)

 

Erivedge® is indicated for the treatment of adult patients with:
 - symptomatic metastatic basal cell carcinoma

 - locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy

(This is a brief indication for use; for details see SPC)

SPC - Erivedge® 150 mg hard capsules

PIL - Erivedge® 150 mg hard capsules

 

RXUKNONP00238h | Date of preparation: November 2015

 

Esbriet® ▼ (pirfenidone)

Esbriet® ▼ (pirfenidone)

Esbriet® is indicated in adults for the treatment of mild to moderate Idiopathic Pulmonary Fibrosis (IPF).

(This is a brief indication for use; for details see SPC)

SPC - Esbriet® 267 mg hard capsules

PIL - Esbriet® 267 mg hard capsules

 

RXUKNONP00238i | Date of preparation: November 2015

Fuzeon® (enfuvirtide)

Fuzeon® (enfuvirtide)

 

Indicated in combination with other antiretroviral medicinal products for the treatment of HIV-1 infected patients.

(This is a brief indication for use; for details see SPC) 

SPC - Fuzeon® 90mg/ml Powder and Solvent for Solution for Injection
PIL - Fuzeon® 90mg/ml Powder and Solvent for Solution for Injection

 

RXUKNONP00238j | Date of preparation: November 2015

 

Gazyvaro® ▼ (obinutuzumab)

Gazyvaro® ▼ (obinutuzumab)

Chronic Lymphocytic Leukaemia (CLL)
Gazyvaro® in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.

Follicular Lymphoma (FL)
Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

SPC - Gazyvaro® 1,000 mg concentrate for solution for infusion

PIL - Gazyvaro® 1,000 mg concentrate for solution for infusion

 

RXUKNONP00238k(1) | Date of preparation: June 2016

Herceptin® (trastuzumab)

Herceptin® (trastuzumab)

 

Used in the treatment of HER2-positive early and metastatic breast cancer, and HER2-positive metastatic gastric cancer.

(This is a brief indication for use; for details see SPC) 

SPC - Herceptin® 150mg Powder for Concentrate for Solution for Infusion
PIL - Herceptin® 150mg Powder for Concentrate for Solution for Infusion

 

Used in the treatment of HER2-positive early and metastatic breast cancer.

(This is a brief indication for use; for details see SPC) 

SPC - Herceptin® 600mg/5ml Solution for Injection
PIL - Herceptin® 600mg/5ml Solution for Injection

 

RXUKNONP00238l | Date of preparation: November 2015

 

Hypnovel® (midazolam)

Hypnovel® (midazolam)

 

Used for sedation and anaesthesia.

(This is a brief indication for use; for details see SPC) 

PIL - Hypnovel® 10mg/2ml Solution for Injection
SPC - Hypnovel® 10mg/2ml Solution for Injection

 

RXUKNONP00238m | Date of preparation: November 2015

 

Invirase® (saquinavir)

Invirase® (saquinavir)

 

Indicated for the treatment of HIV-1 infected adult patients, in combination with ritonavir and other antiretroviral medicinal products.

(This is a brief indication for use; for details see SPC) 

SPC - Invirase® 500 mg Film-Coated Tablets
PIL - Invirase® 500mg Film-Coated Tablets

 

RXUKNONP00238n | Date of preparation: November 2015

 

Kadcyla® ▼ (trastuzumab emtansine)

Kadcyla® ▼ (trastuzumab emtansine)

 

Used in the treatment of HER2-positive advanced breast cancer.

(This is a brief indication for use; for details see SPC) 

SPC - Kadcyla® 100 mg and 160 mg powder for concentrate for solution for infusion

PIL - Kadcyla® 100 mg and 160 mg powder for concentrate for solution for infusion

 

RXUKNONP00238o | Date of preparation: November 2015

 

Konakion® (phytomenadione (vitamin K1))

Konakion® (phytomenadione (vitamin K1))

 

Used as a coumarin type anticoagulant antidote, and in the treatment of haemorrhage or threatened haemorrhage associated with a low blood level of prothrombin or factor VII.

(This is a brief indication for use; for details see SPC) 

SPC - Konakion® MM
PIL - Konakion® MM

Used in the prevention and treatment of vitamin K deficiency bleeding in babies and young children, and as a coumarin type anticoagulant antidote.

(This is a brief indication for use; for details see SPC) 

SPC - Konakion® MM Paediatric
PIL - Konakion® MM Paediatric

 

RXUKNONP00238p | Date of preparation: November 2015

 

Kytril® (granisetron)

Kytril® (granisetron)

 

Used in the prevention and treatment of nausea and vomiting associated with chemotherapy or radiotherapy.

(This is a brief indication for use; for details see SPC)


PIL - Kytril® Tablets 1mg and 2mg
SPC - Kytril® Tablets 1mg
SPC - Kytril® Tablets 2mg

 

RXUKNONP00238q | Date of preparation: November 2015

 

Lariam® (mefloquine)

Lariam® (mefloquine)

 

Used in the prophylaxis and treatment of patients with malaria.

(This is a brief indication for use; for details see SPC) 

SPC - Lariam®
PIL - Lariam®

 

RXUKNONP00238r | Date of preparation: November 2015

 

MabThera® (rituximab)

MabThera® (rituximab)

 

MabThera® concentrate for solution for infusion - Indicated for the treatment of certain types of non-Hodgkin’s lymphoma, chronic lymphocytic leukaemia, severe active rheumatoid arthritis and induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).

(This is a brief indication for use; for details see SPC) 

SPC - Mabthera® 100mg and 500mg Concentrate for Solution for Infusion
PIL - Mabthera® 100mg and 500mg Concentrate for Solution for Infusion

MabThera® 1400 mg solution for subcutaneous injection -  Indicated in adults for Non-Hodgkin's lymphoma (NHL).

 

(This is a brief indication for use; for details see SPC) 

SPC - MabThera® 1400 mg solution for subcutaneous injection 
PIL - MabThera® 1400 mg solution for subcutaneous injection 

 

RXUKNONP00238s | Date of preparation: November 2015

 

Madopar® (levodopa/benserazide)

Madopar® (levodopa/benserazide)

 

Used in the treatment of Parkinsonism.

(This is a brief indication for use; for details see SPC) 

SPC - Madopar® 62.5 mg Hard Capsules
SPC - Madopar® 125 mg Hard Capsules
SPC - Madopar® 250 mg Hard Capsules
SPC - Madopar® 62.5 mg Dispersible Tablets
SPC - Madopar® 125 mg Dispersible Tablets
SPC - Madopar® CR 125 mg Prolonged Release Hard Capsules
PIL - Madopar® Hard Capsules
PIL - Madopar® Dispersible Tablets
PIL - Madopar® CR 125 mg Prolonged Release Hard Capsules

 

RXUKNONP00238t | Date of preparation: November 2015

 

Mircera® (methoxy polyethylene glycol-epoetin beta)

Mircera® (methoxy polyethylene glycol-epoetin beta)

 

Indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD).

(This is a brief indication for use; for details see SPC) 

SPC - Mircera® Solution for Injection in Pre-Filled Syringe
PIL - Mircera® Solution for Injection in Pre-Filled Syringe

 

RXUKNONP00238u | Date of preparation: November 2015

 

NeoRecormon® (epoetin beta)

NeoRecormon® (epoetin beta)

 

Used to treat patients with symptomatic anaemia associated with chronic kidney disease (CKD) and to treat chemotherapy-related anaemia in cancer patients.

(This is a brief indication for use; for details see SPC) 

SPC - NeoRecormon® Solution for Injection in Pre-Filled Syringe
PIL - NeoRecormon® Solution for Injection in Pre-Filled Syringe

 

RXUKNONP00238w | Date of preparation: November 2015

 

Pegasys® (pegylated Interferon alfa-2a)

Pegasys® (pegylated Interferon alfa-2a)

Used in the treatment of chronic hepatitis B and C.

(This is a brief indication for use; for details see SPC) 

SPC - Pegasys 135 mcg and 180 mcg solution for injection in pre-filled pen

PIL - Pegasys 135mcg and 180mcg solution for injection in pre-filled pen

PIL - Pegasys 90 mcg, 135 mcg, 180 mcg Solution for Injection in Pre-filled Syringe

SPC - Pegasys 90mcg, 135mcg and 180mcg solution for injection in Pre-filled Syringe

 

RXUKNONP00238x(1) | Date of preparation: November 2016

 

Perjeta® ▼ (pertuzumab)

Perjeta® ▼ (pertuzumab)

 

Used in the treatment of HER2-positive metastatic breast cancer

(This is a brief indication for use; for details see SPC)

Perjeta® 420 mg Concentrate for Solution for Infusion

PIL - Perjeta® 420 mg Concentrate for Solution for Infusion
SPC - Perjeta® 420 mg Concentrate for Solution for Infusion

 

RXUKNONP00238y | Date of preparation: November 2015

 

Pulmozyme® (dornase alfa)

Pulmozyme® (dornase alfa)

 

Used in the management of cystic fibrosis.

(This is a brief indication for use; for details see SPC) 

PIL - Pulmozyme®
SPC - Pulmozyme® 2500 U/ 2.5ml Nebuliser Solution

 

RXUKNONP00238z | Date of preparation: November 2015

 

Roaccutane® (isotretinoin)

Roaccutane® (isotretinoin)

 

Used in the treatment of severe forms of acne.

(This is a brief indication for use; for details see SPC) 

PIL - Roaccutane® 10mg and 20mg Soft Capsules
SPC - Roaccutane® 10mg Soft Capsules
SPC – Roaccutane® 20mg Soft Capsules

 

RXUKNONP00238ab | Date of preparation: November 2015

 

RoActemra® (tocilizumab)

RoActemra® (tocilizumab)

 

RoActemra® concentrate for solution for infusion - Used in the treatment of adults with moderate to severe active rheumatoid arthritis. Also indicated for the treatment of active systemic juvenile idiopathic arthritis and juvenile idiopathic polyarthritis.

(This is a brief indication for use; for details see SPC) 

SPC - RoActemra® 20mg/ml Concentrate for Solution for Infusion
PIL – RoActemra® 20mg/ml Concentrate for Solution for Infusion

RoActemra® solution for injection in pre-filled syringe - Used in the treatment of adults with moderate to severe active rheumatoid arthritis.

 

(This is a brief indication for use; for details see SPC)

SPC - RoActemra® 162 mg solution for injection in pre-filled syringe
PIL- RoActemra® 162 mg solution for injection in pre-filled syringe

 

RXUKNONP00238aa | Date of preparation: November 2015

 

Rocaltrol® (calcitriol)

Rocaltrol® (calcitriol)

 

Used in the treatment of post-menopausal osteoporosis and renal osteodystrophy.

(This is a brief indication for use; for details see SPC) 

SPC - Rocaltrol® 0.25mcg and 0.5mcg Capsules
PIL - Rocaltrol® 0.25mcg and 0.5mcg Capsules

 

RXUKNONP00238ac | Date of preparation: November 2015

 

Rocephin® (ceftriaxone)

Rocephin® (ceftriaxone)

 

Used in the prevention and treatment of bacterial infections.

(This is a brief indication for use; for details see SPC) 

SPC - Rocephin® 250mg, 1g and 2g Vials
PIL - Rocephin® 250mg, 1g and 2g Vials

 

RXUKNONP00238ad | Date of preparation: November 2015

 

Roferon-A® (interferon alfa-2a)

Roferon-A® (interferon alfa-2a)

 

Used in the treatment of certain types of solid tumours and cancers of the blood and hepatitis B and C.

(This is a brief indication for use; for details see SPC) 

SPC - Roferon-A® Pre-Filled Syringe 3MIU Pre-filled Syringe
PIL - Roferon-A® Pre-filled Syringe
SPC - Roferon-A Pre-Filled Syringe 4.5MIU Pre-filled Syringe
SPC - Roferon-A® Pre-Filled Syringe 6MIU Pre-filled Syringe
SPC - Roferon-A® Pre-Filled Syringe 9MIU Pre-filled Syringe

 

RXUKNONP00238ae | Date of preparation: November 2015

 

Tamiflu® (oseltamivir)

Tamiflu® (oseltamivir)

 

For the prevention and treatment of influenza.

(This is a brief indication for use; for details see SPC)

SPC - Tamiflu® 6 mg/ml powder for oral suspension

PIL - Tamiflu® 6 mg/ml powder for oral suspension 

PIL - Tamiflu® 30mg Hard Capsules

PIL - Tamiflu® 45mg Hard Capsules

PIL - Tamiflu® 75mg Hard Capsule

SPC - Tamiflu 30 mg, 45 mg and 75 mg Hard Capsules

 

RXUKNONP00238af(1) | Date of preparation: January 2017

 

Tarceva® (erlotinib)

Tarceva® (erlotinib)

 

For the treatment of lung and pancreatic cancer.

(This is a brief indication for use; for details see SPC)

SPC - Tarceva® 25mg, 100mg and 150mg Film-Coated Tablets
PIL - Tarceva® 25mg, 100mg and 150mg Film- Coated Tablets

 

RXUKNONP00238ag | Date of preparation: November 2015

 

Valcyte® (valganciclovir)

Valcyte® (valganciclovir)

 

Used in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, and prevention of CMV disease in organ transplant patients.

(This is a brief indication for use; for details see SPC)

SPC - Valcyte® 450mg Film-Coated Tablets
PIL - Valcyte® 450mg Film-Coated Tablets
SPC - Valcyte® Powder for Oral Solution
PIL - Valcyte® Powder for Oral Solution

 

RXUKNONP00238ai | Date of preparation: November 2015

 

Xeloda® (capecitabine)

Xeloda® (capecitabine)

 

Used in the treatment of breast, colon, colorectal and gastric cancer.

(This is a brief indication for use; for details see SPC)

SPC - Xeloda® 150mg and 500mg Tablets
PIL - Xeloda® 150mg Tablets
PIL - Xeloda® 500mg Tablets

 

RXUKNONP00238aj | Date of preparation: November 2015

 

Xenical® (orlistat)

Xenical® (orlistat)

 

Used in the treatment of obesity.

(This is a brief indication for use; for details see SPC)

SPC - Xenical® 120mg Hard Capsules
PIL - Xenical® 120mg Hard Capsules

 

RXUKNONP00238ak | Date of preparation: November 2015

 

Zelboraf® (vemurafenib)

Zelboraf® (vemurafenib)

 

Used in the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma.

(This is a brief indication for use; for details see SPC)

SPC - Zelboraf® 240 mg Film-coated Tablets
PIL - Zelboraf® 240 mg Film-coated Tablets

 

RXUKNONP00238al(1) | Date of preparation: September 2016